Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. | Clini

We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase (PAP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, nonmetastatic, noncastrate prostate cancer (NCT01341652). The

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.